P

Pierrel SpA
MIL:PRL

Watchlist Manager
Pierrel SpA
MIL:PRL
Watchlist
Price: 1.745 EUR Market Closed
Market Cap: €95.9m

Net Margin

9.5%
Current
Improving
by 1.9%
vs 3-y average of 7.6%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
9.5%
=
Net Income
€3.1m
/
Revenue
€33m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
9.5%
=
Net Income
€3.1m
/
Revenue
€33m

Peer Comparison

Country Company Market Cap Net
Margin
IT
Pierrel SpA
MIL:PRL
95.9m EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
530.8B USD
Loading...
CH
Roche Holding AG
SIX:ROG
278.2B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
212.8B GBP
Loading...
CH
Novartis AG
SIX:NOVN
222.3B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
267.6B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
147.1B USD
Loading...
FR
Sanofi SA
PAR:SAN
97.2B EUR
Loading...

Market Distribution

In line with most companies in Italy
Percentile
68th
Based on 1 294 companies
68th percentile
9.5%
Low
-24 712% — 1.6%
Typical Range
1.6% — 10.1%
High
10.1% — 3 667.8%
Distribution Statistics
Italy
Min -24 712%
30th Percentile 1.6%
Median 5.3%
70th Percentile 10.1%
Max 3 667.8%

Pierrel SpA
Glance View

Market Cap
95.9m EUR
Industry
Pharmaceuticals

Pierrel SpA engages in the development, manufacturing, and marketing of medical therapies for the pharmaceutical, bio-pharmaceutical, and life science industries. The company is headquartered in Capua, Caserta. The company went IPO on 2006-05-23. The firm specializes in the pharmaceutical research, development and the manufacture of medicines. The company operates through three segments. The Contract Manufacturing segment covers research and development of various types of drugs, such as Tube vials, bottles, ampoules, drops, sprays, tablets and gels. The company manufactures the drugs in the production facility in Capua, which consists of warehouses, chemical and microbiological laboratories, offices and utilities buildings. The Pharma segment is active in the development, registration and licensing of new drugs and medical devices. The Tech-driven Contract Research & Development Organization segment provides research of existing drugs for the treatment of rare diseases, among others.

PRL Intrinsic Value
Not Available
P
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
9.5%
=
Net Income
€3.1m
/
Revenue
€33m
What is Pierrel SpA's current Net Margin?

The current Net Margin for Pierrel SpA is 9.5%, which is above its 3-year median of 7.6%.

How has Net Margin changed over time?

Over the last 3 years, Pierrel SpA’s Net Margin has decreased from 17% to 9.5%. During this period, it reached a low of 5.6% on Dec 31, 2022 and a high of 17% on May 30, 2020.

Back to Top